How many 8-K filings has Liminatus Pharma, Inc. filed?

Liminatus Pharma, Inc. (LIMNW) has 9 8-K (Current Event Report) filings on record, spanning May 2025 to Nov 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Liminatus Pharma, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Liminatus Pharma, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Liminatus Pharma, Inc. (LIMNW) — 8-K Filings

All 8-K filings from Liminatus Pharma, Inc.. Browse 9 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (9)

Liminatus Pharma Faces Delisting Concerns — Nov 25, 2025 Risk: high
Liminatus Pharma, Inc. filed an 8-K on November 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The compan
Liminatus Pharma Faces Delisting Notice — Aug 25, 2025 Risk: high
Liminatus Pharma, Inc. filed an 8-K on August 25, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, previously k
Liminatus Pharma Files 8-K — Aug 14, 2025 Risk: low
Liminatus Pharma, Inc. filed an 8-K on August 14, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly Iri
Liminatus Pharma Enters Material Definitive Agreement — Jul 17, 2025 Risk: medium
Liminatus Pharma, Inc. entered into a material definitive agreement on July 16, 2025, related to unregistered sales of equity securities. The company, formerly
Liminatus Pharma Announces Board and Officer Changes — Jul 11, 2025 Risk: low
Liminatus Pharma, Inc. announced on July 10, 2025, changes in its board of directors and officer appointments. The company, formerly known as Iris Parent Holdin
Liminatus Pharma to Raise $2.4M via Stock and Warrant Offering — Jul 3, 2025 Risk: medium
Liminatus Pharma, Inc. announced on July 2, 2025, that it has entered into a securities purchase agreement. The company plans to sell approximately 1.2 million
Liminatus Pharma Files 8-K — Jun 24, 2025 Risk: low
Liminatus Pharma, Inc. filed an 8-K on June 23, 2025, reporting other events and financial statements. The company, formerly Iris Parent Holding Corp., is incor
Liminatus Pharma Faces Delisting Concerns — Jun 4, 2025 Risk: high
Liminatus Pharma, Inc. filed an 8-K on June 4, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, formerly known
Liminatus Pharma Completes Iris Parent Acquisition — May 6, 2025 Risk: medium
Liminatus Pharma, Inc. announced on April 30, 2025, the completion of its acquisition of Iris Parent Holding Corp. The company also entered into a material defi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX